July 22, 2025

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Re:	Brainstorm Cell Therapeutics Inc.
	Registration Statement on Form S-3
	File No. 333-288322

Ladies and Gentlemen:

On June 25, 2025, Brainstorm Cell Therapeutics Inc., a Delaware corporation (the “Company”), filed a Registration Statement on Form S-3 (File No. 333-288322) (the “Registration Statement”), with the Securities and Exchange Commission (the “Commission”). In accordance with Rule 477 under the Securities Act of 1933, as amended (the “Securities Act”), the Company hereby respectfully makes this application to withdraw the Registration Statement, together with all exhibits thereto.

No securities have been issued or sold under the Registration Statement. The Registration Statement has not been declared effective by the Commission.

The Company respectfully requests that the Commission issue an order granting withdrawal of the Registration Statement. The Company further requests that all fees paid to the Commission in connection with the filing of the Registration Statement be credited for future use in accordance with Rule 457(p) of the Act.

Your assistance in this matter is greatly appreciated. If you have any questions regarding this application for withdrawal, please contact me at (201) 488-0460 or the Company’s counsel, Faith Charles at (212) 344-5680.

Very truly yours,
BRAINSTORM CELL THERAPEUTICS INC.
By:	/s/ Chaim Lebovits
Name:	Chaim Lebovits
Title:	Chief Executive Officer